Fosaprepitant

證據等級: L5

預測適應症: 10 個

Fosaprepitant: From CINV Prevention to Nephrogenic Syndrome of Inappropriate Antidiuresis

One-Sentence Summary

Fosaprepitant is the intravenous prodrug of aprepitant, an NK1/Substance P receptor antagonist used as supportive care to prevent chemotherapy-induced nausea and vomiting (CINV) — this pharmacology is evident from the trial evidence in this pack, though it is not captured in the structured MOA field. TxGNN's top-ranked prediction, Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD), scores 99.92% but is explicitly flagged in the evidence pack as a mechanistically unsupported, isolated network signal — no clinical trials or literature support this indication. Across all 10 candidates screened for this drug, only one (retinitis, rank 7) shows preliminary mechanistic plausibility, and it remains preclinical only.

Quick Overview

Item	Content
Original Indication	Chemotherapy-induced nausea and vomiting (CINV) prevention — inferred from associated trial evidence in this pack; not captured in structured fields
Predicted New Indication	Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD)
TxGNN Prediction Score	99.92%
Evidence Level	L5 (model prediction only, no supporting trials or literature)
Germany Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Portfolio Screening Overview (10 Predicted Indications)

This evidence pack screened 10 TxGNN candidates for Fosaprepitant. Nine were flagged as network artifacts with no supporting evidence; one reached a preliminary research-question stage.

Rank	Predicted Indication	TxGNN Score	Evidence Level	Recommendation	Note
1	Nephrogenic syndrome of inappropriate antidiuresis	99.92%	L5	Hold	AVPR2 mutation disease; no NK1 pathway link
2	Pneumocystosis	99.87%	L5	Hold	Fungal infection; no antifungal activity reported
3	Leprosy	99.82%	L5	Hold	Mycobacterial infection; no mechanistic link
4	Cryptococcal meningitis	99.79%	L5	Hold	Fungal CNS infection; no supporting data
5	Multiple endocrine neoplasia	99.76%	L4	Hold	Trials exist but are CINV support-care studies in cancer patients, not MEN-directed therapy — indication mismatch
6	Intracranial abscess	99.75%	L5	Hold	Bacterial infection; no mechanistic link
7	Retinitis	99.68%	L4	Research Question	Preclinical: Fosaprepitant blocks UVR-B-induced NK1 receptor expression in mouse ocular tissue
8	Plasmodium falciparum malaria	99.64%	L5	Hold	No antimalarial activity reported
9	Echinococcus granulosus infection	99.50%	L5	Hold	Parasitic infection; no mechanistic link
10	Hyperargininemia	99.41%	L5	Hold	Inherited metabolic disease; no mechanistic link

Why is This Prediction Reasonable?

Detailed structured mechanism-of-action data is not available for Fosaprepitant in this evidence pack. However, the rationale text accompanying each prediction consistently identifies Fosaprepitant as an NK1 (neurokinin-1) / Substance P receptor antagonist, consistent with its known clinical use as an antiemetic prodrug of aprepitant for chemotherapy-induced nausea and vomiting.

For the top-ranked prediction, NSIAD, the evidence pack itself states there is no known mechanistic relationship: NSIAD is caused by gain-of-function mutations in the AVPR2 (vasopressin V2 receptor) gene, a pathway entirely unrelated to NK1/Substance P signaling. No clinical trials or literature exist to support this connection. The evidence pack explicitly characterizes this as an isolated signal generated by the TxGNN network's topology rather than a validated biological hypothesis.

Of the ten candidates screened, only retinitis (rank 7) shows a plausible, if preliminary, mechanistic rationale: a preclinical mouse study (PMID 32058829) demonstrated that Fosaprepitant blocks UVR-B-induced NK1 receptor upregulation in ocular tissue, consistent with Substance P's known role in ocular neurogenic inflammation. This remains non-clinical evidence only. The multiple endocrine neoplasia (rank 5) candidate has associated clinical trials, but all are CINV supportive-care studies in cancer patients undergoing chemotherapy or transplantation — not trials targeting MEN tumors — representing a population-overlap artifact rather than a genuine indication link.

Clinical Trial Evidence

Currently no related clinical trials registered for Nephrogenic Syndrome of Inappropriate Antidiuresis.

Literature Evidence

Currently no related literature available for Nephrogenic Syndrome of Inappropriate Antidiuresis.

Germany Market Information

Fosaprepitant currently holds no marketing authorizations in Germany (0 licenses on record; market status: Not Marketed). No product/dosage-form data is available.

Safety Considerations

Please refer to the package insert for safety information. Key warnings, contraindications, and drug-drug interaction data are not available in this evidence pack (TFDA label retrieval is flagged as a Blocking data gap — DG001 — preventing formal S1 safety assessment).

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction (NSIAD) has a high TxGNN score but is explicitly unsupported by any mechanistic, preclinical, or clinical evidence — the evidence pack itself classifies it as an isolated network artifact. Combined with the drug's unmarketed status in Germany and blocking gaps in label/MOA data, there is no basis to advance this candidate.

To proceed, the following is needed:

TFDA/BfArM label PDF retrieval and parsing for warnings and contraindications (blocking gap DG001)
Structured MOA data via DrugBank API (gap DG002)
If pursuing the portfolio further, prioritize retinitis (rank 7) as a research question: preclinical validation (e.g., in vivo efficacy beyond the single UVR-B mouse model) would be needed before any clinical evaluation
Independent mechanistic review of the MEN (rank 5) trials to confirm they do not represent a genuine signal beyond population overlap
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.